atorvastatin


Also found in: Dictionary, Thesaurus, Wikipedia.

atorvastatin

 [ah-tor″vah-stat´in]
an agent that inhibits cholesterol synthesis, used as the calcium salt in treatment of primary hypercholesterolemia and hyperlipidemia; administered orally.

atorvastatin

(ə-tôr′və-stăt′n)
n.
A statin, (C33H34FN2O5)2Ca·3H2O, that blocks the body's synthesis of cholesterol and is used to treat hyperlipidemia.

atorvastatin

A cholesterol-lowering HMG-CoA reductase inhibitor, or statin, which improves the lipid profile—LDL-C reduced 35% to 60%; TGs reduced 20–37%; HDL-C increased 5–9%.
 
Adverse effects
Liver dysfunction, rhabdomyolysis with acute renal failure secondary to myoglobinuria, constipation, flatulence, dyspepsia, abdominal pain, myalgia, weakness.
 
Indications
Homozygous familial hypercholesterolaemia, severe refractory hypercholesterolaemia.

atorvastatin

Lipitor® Cardiology A cholesterol-lowering HMG-CoA reductase inhibitor or statin which improves the lipid profile–↓ 35% to 60% LDL-C; ↓TGs 20–37%;↑ 5–9% HDL-C Adverse effects Liver dysfunction, rhabdomyolysis with acute renal failure 2º to myoglobinuria, constipation, flatulence, dyspepsia, abdominal pain, myalgia, weakness. See AVERT, Statin.

atorvastatin

A cholesterol-lowering drug. A brand name is Lipitor. See STATINS.
References in periodicals archive ?
During a median follow-up of 2.5 years, 1.6 per cent of patients who received atorvastatin and 2.4 per cent of patients receiving placebo experienced cardiovascular death, heart attack, stroke, transient ischemic attack, or any arterial revascularisation.
The first-order derivative overlaid spectra of atorvastatin calcium and fenofibrate denoted that there was no zero crossing point for atorvastatin calcium for quantification of fenofibrate (Figure 2).
Yamakawa et al reported a significant increase in glycated hemoglobin (HbA1c) in patients with diabetes receiving Atorvastatin treatment for 3 months, whereas only a minimal change in HbA1c in patients receiving Pitavastatin14.
Cell viability and cytotoxic effects caused by atorvastatin were determined by a WST-1 assay.
Different statins have varied propensities for causing self-limited myopathy, with atorvastatin and simvastatin associated with higher rates of myopathy than rosuvastatin; however, there is no established association between specific statins and the occurrence of SINAM [7, 8].
PubMed database was used to search for publications of interest using as keywords "atorvastatin AND diabetes." Eligible studies were primary studies of every design (observational studies, cross-sectional, cohort, case studies, case series, clinical trials, etc.) published in English until 30/ 04/2015 (date of last search).
Conclusion: Atorvastatin used as an adjuvant therapy with currently existing standard therapy (topical betamethasone) in patients having mild to moderate plaque type psoriasis reduces disease severity and cardiovascular risks.
Oral administration of atorvastatin (10 mg) led to decline in CFFF from the baseline score taken before intake of test drug.
Analysis of the proliferation assays shows that both atorvastatin solution and atorvastatin-medicated dentifrice reduced the percentage of CD4+ T cell proliferation compared with control and dentifrice without atorvastatin.
Our case highlights a serious drug induced myotoxicity from high dose atorvastatin, two and a half months after instituting ticagrelor and continuing with amlodipine.
At the same time, the patient remained on her therapeutic regimen, which included atorvastatin 20 mg once daily.
Forty-five rats were randomly allocated to the following five groups (n = 9 per group): (1) control group (dehydration + furosemide, without CM administration); (2) CIAKI group; (3) CI-AKI + rosuvastatin group (10 mg/kg, AstraZeneca Pharmaceutical Co., Ltd., UK); (4) CI-AKI + simvastatin group (80 mg/kg, Merck & Co., Inc., USA); and (5) CI-AKI + atorvastatin group (20 mg/kg, Pfizer Pharmaceuticals Ltd., USA).